Kurs
+1,77%
Kurs
+1,77%
Open
23,10
High
23,20
Low
22,05
Close
23,00
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
6,63 MNOK
Likviditet
6,63 MNOK
Rel. mcap
1,98%
Antal aktier
291 407
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2026-02-19 | 13:00 | Bokslutskommuniké 2025 |
| 2025-11-19 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-21 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-20 | N/A | Årsstämma |
| 2025-02-26 | 13:00 | Bokslutskommuniké 2024 |
| 2024-11-13 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-10 | - | Extra Bolagsstämma 2024 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | Split BGBIO 100:1 |
| 2024-05-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-24 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-14 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-22 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-22 | - | Årsstämma |
| 2023-04-21 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-15 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-29 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2022-04-28 | - | Årsstämma |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2022-01-06 | - | Extra Bolagsstämma 2022 |
| 2021-11-16 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2021-03-19 | - | Årsstämma |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-12-09 | - | Extra Bolagsstämma 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-19 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-17 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2020-03-16 | - | Årsstämma |
| 2020-02-11 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-19 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-14 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2019-03-13 | - | Årsstämma |
| 2019-02-19 | - | Bokslutskommuniké 2018 |
| 2018-11-13 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-15 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2018-05-14 | - | Årsstämma |
| 2018-03-09 | - | Extra Bolagsstämma 2018 |
| 2018-02-13 | - | Bokslutskommuniké 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-23 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2017-03-22 | - | Årsstämma |
| 2016-06-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2016-06-21 | - | Årsstämma |
| 2015-06-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2015-06-22 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2023-12-12 07:00:05
Bergen, Norway, December 12, 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced that Martin Olin, Chief Executive
Officer of BerGenBio, will present at the 14th Annual DNB Nordic Healthcare
Conference in Oslo, Norway, on Thursday, December 14, 2023, at 12:35pm CET.
The presentation will be made available on the Company website in the
presentations section on the day of the event:
www.bergenbio.com/investors/presentations/
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations / Media Relations
Jan Lilleby
jl@lillebyfrisch.no
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visitwww.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.